Table 2.
Number of infections averted via pre-exposure prophylaxis (PrEP) use (2015–2032) in comparison to no PrEP.
| Cumulative starters | PrEP effectiveness (%) |
|||||
|---|---|---|---|---|---|---|
| 45% | 55% | 65% | 75% | 85% | 95% | |
| 120,000 | 810 (1.5%) | 850 (1.6%) | 900 (1.7%) | 945 (1.8%) | 995 (1.9%) | 1025 (1.9%) |
| 100,000 | 660 (1.2%) | 700 (1.3%) | 745 (1.4%) | 780 (1.5%) | 810 (1.5%) | 850 (1.6%) |
| 80,000 | 550 (1.0%) | 580 (1.1%) | 625 (1.2%) | 645 (1.2%) | 675 (1.3%) | 685 (1.3%) |
| 60,000 | 435 (0.8%) | 460 (0.9%) | 485 (0.9%) | 495 (0.9%) | 525 (1.0%) | 550 (1.0%) |
| 40,000 | 290 (0.5%) | 310 (0.6%) | 345 (0.6%) | 355 (0.7%) | 370 (0.7%) | 385 (0.7%) |
The analysis is stratified by effectiveness of PrEP in preventing HIV infections and number of cumulative starters, with 10% using PrEP consistently defined as daily PrEP use with with high retention (average duration of five years) and a 95% effectiveness.